ストックスクリーナーアプリを入手
2.75
0.36%
-0.010
前日終値:
$2.76
開ける：
$2.77
24時間の取引高:
28,744
Relative Volume:
0.16
時価総額：
$93.05M
収益：
-
当期純損益:
$-13.27M
株価収益率:
-16.77
EPS:
-0.164
ネットキャッシュフロー:
$-7.70M
1週間 パフォーマンス:
-8.03%
1か月 パフォーマンス:
+11.34%
6か月 パフォーマンス:
+161.90%
1年 パフォーマンス:
+103.70%
1日の値動き範囲:
$2.70
$2.7816
1週間の範囲:
$2.67
$2.9803
52週間の値動き範囲:
$0.8075
$3.11
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.75 | 103.81M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited (OKYO) 最新ニュース
What is the risk reward ratio of investing in OKYO Pharma Limited stockInvest smarter with real-time trading alerts - jammulinksnews.com
Published on: 2025-07-27 19:17:36 - jammulinksnews.com
How Resilient Is OKYO Pharma Limited Stock During Economic DownturnsFast Moving Stock Alerts - Newser
What catalysts could drive OKYO Pharma Limited stock higher in 2025Discover stocks with massive upside potential - jammulinksnews.com
Why OKYO Pharma Limited stock attracts strong analyst attentionMarket Beating Strategy - Newser
How OKYO Pharma Limited stock performs during market volatilityControlled Risk High Reward Plan - Newser
OKYO Pharma Limited Stock Analysis and ForecastMarket-beating returns - PrintWeekIndia
What analysts say about OKYO Pharma Limited stockMassive stock growth - PrintWeekIndia
What institutions are buying OKYO Pharma Limited stock nowFree Market Dynamics Reports - jammulinksnews.com
Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile
What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional
Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional
OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news
OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire
OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria
OKYO Slides Despite Fresh R&D Funding - Baystreet.ca
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada
Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news
Okyo Pharma Limited (OKYO) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):